Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
July 21, 2008

Gamida Obtains Rights to Amgen Cytokines to Produce Stem Cell Cancer Drug

  • Gamida Cell will use a number of cytokines from Amgen to manufacture StemEx for its pivotal registration study and subsequent commercialization. The product is being developed for hematological malignancies by Gamida Cell in a joint venture with Teva Pharmaceutical.

    Under the terms of the nonexclusive license agreement, Amgen will receive a minority equity interest in Gamida Cell in addition to royalties from sales related to hematological indications.

    StemEx is composed of ex vivo expanded cord blood stem/progenitor cells that are transplanted with nonexpanded cells from the same unit. In November 2007, the first patient enrolled in the international, multicenter trial, underwent a StemEx transplant.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.